Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue
+38.3%
EPS
−294.7%
Free cash flow
+5.09%
Total debt
+40.8%

Quarter to June 2026, against a year earlier

24.11 2.55 −9.56%
Market cap
$5.6B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a

Hims & Hers Health, Inc. 8-K filed Oct 2, 2025

Period ended Sep 28, 2025 · Filed · accepted 4:04 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov